Question-and-Answer Session
Operator
(Operator Instructions).
Harry Stylli
While we wait for our question queue to be compiled or complied, I would like to take a moment to welcome a couple of new additions to our leadership team.
Clinical operations are clearly an important focus for the company. I'm delighted that Mary Rose Keller has joined SEQUENOM as Vice President of Clinical Operations reporting to our Chief Medical Officer, Dr. Allan Bombard. Mary Rose brings more than 25 years of clinical research experience across a broad range of therapeutic areas as well as diagnostic and treatment modalities.
She has significant prior experience in all facets of clinical development working with biotech and pharmaceutical companies, academic institutions and contract research organizations, including managing numerous global regulatory submissions and approvals.
Ramping up for laboratory developed test launches is going to be a major focus for our commercial operations group in the coming months. It is worth mentioning another new addition to the team, Joe Zimmerman, who has joined as Vice President of Managed Care. Joe's background includes management positions at AmeriPath and LabCorp. Joe also held several key sales, marketing and managed care positions at UroCor and Dianon prior to the acquisition by LabCorp.
Okay, operator, we're ready for the first question.
Operator
Your first question comes from the line of Elemer Piros with Rodman. Please proceed.
Elemer Piros - Rodman
Good afternoon. Can you hear me?
Harry Stylli
We hear you loud and clear, Elemer.
Elemer Piros - Rodman
A fairly reasonable quarter considering, and just by looking at your guidance for the rest of the year, it seems like you project to experience continued softness because in order to meet even the top and the rear guidance, I have to decrease some of the items here for the second half. Is that a correct way at looking at the situation?
Paul Hawran
Yeah. I think actually we are actually waiting for the third quarter to get a better handle on a full year results right now, Elemer. But right now we just want to be cautious and stay with the same guidance that we've had, modified for things that we know that are absolute. So, that's the reason why we've kept it essentially unchanged.
Elemer Piros - Rodman
I tried to reconcile the guidance, Paul, and just back of the envelope calculation assumed 35 million revenue, cost of goods roughly 15, and just keeping the R&D at the same level as we are roughly 40 for the year, that's maybe a little bit too much, selling and marketing around $30 million, G&A at $32 million, I'm coming up with a number that is closer to 115 in total costs and expenses. If I back out the 35 million revenue projected, then I'm still getting roughly an $80 million loss, which is in contrast to what you have projected. Where do I go wrong?
- To read the full transcript on Seeking Alpha, click here »
